Table 1.
Baseline characteristics of the RA group and the control group.
| Parameter | RA Group (n = 70) |
Control Group (n = 70) | p * |
|---|---|---|---|
| Female sex (N,%) | 64 (91.4) | 61 (87.1) | 0.737 |
| Age (years) | 55.9 ± 12.5 | 52.5 ± 14.1 | 0.134 |
| Body weight (kg) | 73.2 ± 13.6 | 69.6 ± 14.1 | 0.124 |
| Body height (cm) | 169.1 ± 7.2 | 168.1 ± 10.1 | 0.487 |
| Body mass index (kg/m2) | 25.6 ± 4.2 | 25.0 ± 4.3 | 0.394 |
| SBP (mmHg) | 131.2 ± 17.5 | 126.3 ± 15.2 | 0.078 |
| DBP (mmHg) | 80.9 ± 10.9 | 78.7 ± 11.4 | 0.244 |
| Smoking (N,%) | 22 (31.4) | 16 (22.9) | 0.349 |
| Disease duration (years) † | 15.0 (10.0–20.0) | - | - |
| Rheumatoid factor (N,%) | 46 (65.7) | - | - |
| Anti-CCP (N,%) | 51 (72.8) | - | - |
| DAS28 (score) ‡ | 2.49 ± 0.94 | - | - |
| HAQ (score) | 0.83 ± 0.60 | - | - |
| csDMARD | 50 (71.4) | - | - |
| tsDMARD | 10 (14.2) | - | - |
| bDMARD | 60 (85.8) | - | - |
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, Disease Activity Score 28; HAQ, Health Assessment Questionnaire; scDMARD, conventional synthetic disease-modifying antirheumatic drug; tsDMARD, targeted synthetic disease-modifying antirheumatic drug; bDMARD, biologic disease-modifying antirheumatic drug. Data are presented as the whole number (percentage), the mean ± standard deviation or median (IQR). * chi-square test or t-test for independent samples. † time period since the initial diagnosis. ‡ calculated using the hsCRP values.